JP2023530335A5 - - Google Patents
Info
- Publication number
- JP2023530335A5 JP2023530335A5 JP2022577390A JP2022577390A JP2023530335A5 JP 2023530335 A5 JP2023530335 A5 JP 2023530335A5 JP 2022577390 A JP2022577390 A JP 2022577390A JP 2022577390 A JP2022577390 A JP 2022577390A JP 2023530335 A5 JP2023530335 A5 JP 2023530335A5
- Authority
- JP
- Japan
- Prior art keywords
- relaxin
- section
- chain
- heterodimer fusion
- heterodimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025279747A JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040250P | 2020-06-17 | 2020-06-17 | |
| US63/040,250 | 2020-06-17 | ||
| PCT/EP2021/066309 WO2021255127A1 (en) | 2020-06-17 | 2021-06-16 | Heterodimeric relaxin fusions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279747A Division JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023530335A JP2023530335A (ja) | 2023-07-14 |
| JP2023530335A5 true JP2023530335A5 (https=) | 2024-09-19 |
| JP7797423B2 JP7797423B2 (ja) | 2026-01-13 |
Family
ID=76584509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577390A Active JP7797423B2 (ja) | 2020-06-17 | 2021-06-16 | ヘテロ二量体リラキシン融合物及びその使用 |
| JP2025279747A Pending JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279747A Pending JP2026053559A (ja) | 2020-06-17 | 2025-12-24 | ヘテロ二量体リラキシン融合物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11795205B2 (https=) |
| EP (1) | EP4168434A1 (https=) |
| JP (2) | JP7797423B2 (https=) |
| KR (1) | KR20230024994A (https=) |
| CN (1) | CN115916813B (https=) |
| AR (1) | AR125007A1 (https=) |
| AU (3) | AU2021290997C1 (https=) |
| BR (1) | BR112022025019A2 (https=) |
| CA (1) | CA3186143A1 (https=) |
| CL (1) | CL2022003578A1 (https=) |
| CO (1) | CO2023000038A2 (https=) |
| CR (1) | CR20230015A (https=) |
| EC (1) | ECSP23002960A (https=) |
| IL (1) | IL298786A (https=) |
| MX (1) | MX2022016340A (https=) |
| TW (1) | TWI899263B (https=) |
| WO (1) | WO2021255127A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118510536A (zh) | 2021-11-11 | 2024-08-16 | 泰克托尼治疗股份有限公司 | 松弛素-2融合蛋白类似物及其使用方法 |
| CA3252059A1 (en) | 2022-05-07 | 2025-07-07 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Relaxin fusion protein or analogue and its medical use |
| WO2024015634A2 (en) * | 2022-07-15 | 2024-01-18 | Nutcracker Therapeutics, Inc. | Mrna therapies including sirp-alpha |
| EP4630036A1 (en) | 2022-12-09 | 2025-10-15 | Astrazeneca AB | Dosing regimens using heterodimeric relaxin fusions |
| CN120813595A (zh) | 2023-03-03 | 2025-10-17 | 阿斯利康(瑞典)有限公司 | 包含异源二聚体松弛素融合蛋白的药物制剂及其用途 |
| AU2024270919A1 (en) | 2023-05-18 | 2026-01-15 | Tectonic Operating Company, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US8389475B2 (en) | 2009-08-10 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Relaxin analogs |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| RU2014103288A (ru) * | 2011-07-01 | 2015-08-10 | Байер Интеллектчуал Проперти Гмбх | Слитые полипептиды релаксина и их применение |
| BR112014010580B1 (pt) * | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| AR094147A1 (es) | 2012-12-27 | 2015-07-15 | Bayer Pharma Aktiengellschaft | Polipeptidos de fusion con actividad de relaxina y sus usos |
| CA3244731A1 (en) * | 2014-05-28 | 2025-11-29 | Zymeworks Bc Inc. | Modified antigen binding polypeptide constructs and uses thereof |
| PT3387019T (pt) * | 2015-12-09 | 2022-01-14 | Scripps Research Inst | Proteínas de fusão de imunoglobulina de relaxina e métodos de uso |
| EP3574004A1 (en) * | 2017-01-25 | 2019-12-04 | Medimmune, LLC | Relaxin fusion polypeptides and uses thereof |
-
2021
- 2021-06-16 CA CA3186143A patent/CA3186143A1/en active Pending
- 2021-06-16 US US17/348,825 patent/US11795205B2/en active Active
- 2021-06-16 EP EP21734103.1A patent/EP4168434A1/en active Pending
- 2021-06-16 WO PCT/EP2021/066309 patent/WO2021255127A1/en not_active Ceased
- 2021-06-16 AU AU2021290997A patent/AU2021290997C1/en active Active
- 2021-06-16 CR CR20230015A patent/CR20230015A/es unknown
- 2021-06-16 BR BR112022025019A patent/BR112022025019A2/pt unknown
- 2021-06-16 CN CN202180042080.5A patent/CN115916813B/zh active Active
- 2021-06-16 KR KR1020237001632A patent/KR20230024994A/ko active Pending
- 2021-06-16 MX MX2022016340A patent/MX2022016340A/es unknown
- 2021-06-16 JP JP2022577390A patent/JP7797423B2/ja active Active
- 2021-06-16 IL IL298786A patent/IL298786A/en unknown
- 2021-06-17 AR ARP210101647A patent/AR125007A1/es unknown
- 2021-06-17 TW TW110122051A patent/TWI899263B/zh active
-
2022
- 2022-12-15 CL CL2022003578A patent/CL2022003578A1/es unknown
-
2023
- 2023-01-03 CO CONC2023/0000038A patent/CO2023000038A2/es unknown
- 2023-01-16 EC ECSENADI20232960A patent/ECSP23002960A/es unknown
- 2023-07-01 US US18/346,205 patent/US12187774B2/en active Active
-
2024
- 2024-01-05 AU AU2024200074A patent/AU2024200074B2/en active Active
- 2024-11-25 US US18/958,082 patent/US20250230214A1/en active Pending
-
2025
- 2025-10-20 AU AU2025252658A patent/AU2025252658A1/en active Pending
- 2025-12-24 JP JP2025279747A patent/JP2026053559A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023530335A5 (https=) | ||
| US20250011432A1 (en) | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | |
| TWI648401B (zh) | 生長分化因子１５（ｇｄｆ－１５）構築體 | |
| US5767260A (en) | Antigen-binding fusion proteins | |
| JP2023085476A5 (https=) | ||
| JP2020196744A5 (https=) | ||
| JP2017538395A5 (https=) | ||
| JP2023518434A5 (https=) | ||
| JP2018537966A5 (https=) | ||
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| CN107001468A (zh) | Cd3结合结构域 | |
| JP2016510755A5 (https=) | ||
| TW201536805A (zh) | 具有結合ＣＤ３２Ｂ和ＣＤ７９ｂ能力的雙特異性單價Ｆｃ雙抗體及其用途 | |
| JP2021534220A5 (https=) | ||
| CN118121696A (zh) | 靶向骨的抗体 | |
| JP7793774B2 (ja) | メソテリン結合タンパク質及びその使用 | |
| WO1997049429A1 (en) | Genetically engineered immunoglobulins with specificity for glycated albumin | |
| JP2024546877A5 (https=) | ||
| JP2023554119A5 (https=) | ||
| JP2024539139A5 (https=) | ||
| JP2025124718A5 (https=) | ||
| CA3168444A1 (en) | Bispecific gd2 and b7h2 binding molecules and methods of use | |
| JP7676316B2 (ja) | Ｈｉｖ感染症の処置のためのクロスオーバー二重可変ドメイン（ｃｏｄｖ）フォーマットを使用した三重特異性および／または三価結合性タンパク質 | |
| JP2022545234A (ja) | Ｃｄ３とｃｄ２０を標的とする二重特異性抗体及びその使用 | |
| JP2024546129A5 (https=) |